Your daily source for AI news, tools reviews, and practical guides to artificial intelligence
Converge Bio, an AI-focused drug discovery startup, has successfully raised $25 million in a Series A funding round led by Bessemer Venture Partners, receiving additional investment from key figures at Meta, OpenAI, and Wiz.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with additional investments from executives at Meta, OpenAI, and Wiz. This capital injection aims to accelerate the development of innovative therapies using artificial intelligence.
Converge Bio, an AI-powered drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with participation from executives affiliated with Meta, OpenAI, and Wiz.